Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
33.30
+0.15 (0.45%)
At close: Apr 14, 2026, 4:00 PM EDT
33.02
-0.28 (-0.85%)
After-hours: Apr 14, 2026, 7:35 PM EDT
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts that cover Agios Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $39.88, which forecasts a 19.76% increase in the stock price over the next year. The lowest target is $28 and the highest is $65.
Price Target: $39.88 (+19.76%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Agios Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Hold Maintains $31 → $36 | Hold | Maintains | $31 → $36 | +8.11% | Apr 6, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $28 → $32 | Hold | Maintains | $28 → $32 | -3.90% | Apr 1, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $38 → $46 | Strong Buy | Maintains | $38 → $46 | +38.14% | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $62 → $65 | Strong Buy | Maintains | $62 → $65 | +95.20% | Feb 12, 2026 |
| JP Morgan | JP Morgan | Hold Maintains $20 → $25 | Hold | Maintains | $20 → $25 | -24.92% | Jan 6, 2026 |
Financial Forecast
Revenue This Year
94.52M
from 54.03M
Increased by 74.95%
Revenue Next Year
251.21M
from 94.52M
Increased by 165.77%
EPS This Year
-6.75
from -7.12
EPS Next Year
-5.27
from -6.75
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 122.3M | 367.4M | |||
| Avg | 94.5M | 251.2M | |||
| Low | 65.7M | 154.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 126.4% | 288.6% | |||
| Avg | 75.0% | 165.8% | |||
| Low | 21.5% | 63.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -6.05 | -4.05 | |||
| Avg | -6.75 | -5.27 | |||
| Low | -7.00 | -6.12 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.